Ovulation was successfully induced with luteinising hormone releasing hormone in 28 women with hypothalamic amenorrhoea who had failed to respond to treatment with clomiphene. Luteinising hormone releasing hormone was administered in a pulsatile manner with miniaturised automatic infusion systems. The rate of ovarian follicular maturation, as monitored by serial pelvic ultrasonography, was similar to that observed in spontaneous cycles. Endocrine assessment by serial measurement of gonadotrophin, oestradiol, and progesterone concentrations showed hormone concentrations to be within the normal range. Intravenous treatment was required in only two patients, the remainder
Introduction
Hypogonadotrophic hypogonadism is an important cause of anovulatory infertility.' Though many patients with this disorder respond to antioestrogen clomiphene citrate treatment, an appreciable proportion require treatment with human menopausal gonadotrophin and human chorionic gonadotrophin. Despite close biochemical and ultrasonic supervision treatment with gonadotrophins is associated with a major risk of multiple conception (20%) and ovarian hyperstimulation (3o%). 2 Normal secretion of gonadotrophin depends on the pulsatile release of luteinising hormone releasing hormone by the hypothalamus. [3] [4] [5] The artificial synthesis of this hormone has led to attempts to use it to directly stimulate release of gonadotrophins in patients with hypogonadotrophic hypogonadism. Although Kastin et Results of initial studies suggested that subcutaneous administration of luteinising hormone releasing hormone might not be appropriate,'2 and Leyendecker et al relied on the intravenous route for infusion. "3 14 Other workers, however, have claimed that subcutaneous infusion is effective. '5 16 The incidence of multiple pregnancy after pulsatile treatment with luteinising hormone releasing hormone also seems to be considerably lower than that after gonadotrophin injections. As intravenous infusion can present problems and is potentially hazardous over prolonged periods we undertook a study to 181 investigate the efficacy of subcutaneous pulsatile treatment with luteinising hormone releasing hormone in a group of 28 patients with hypothalamic amenorrhoea of differing aetiologies. We report their response in terms of both ovulation and conception.
Patients and methods
We treated 28 women with amenorrhoea and infertility. All had been investigated according to the protocol of Hull et . Six patients (mean (SD) age 27-3 (6-5) years) had primary amenorrhoea, which was associated with anosmia in five (18) ; in the sixth patient computed tomography showed an empty sella but pituitary function tests gave normal results apart from evidence of hypogonadotrophic hypogonadism. Twenty two patients (mean age 32-3 (6-0) years) had secondary amenorrhoea, its duration ranging from nine to 216 months (mean 50 (8) 21 The injections were administered with a miniaturised automatic pump specifically designed for this purpose at the National Institute for Medical Research, Mill Hill. This pump is based on a previously described direct drive insulin pump. 22 In all patients treatment was initially given by the subcutaneous route with a 27 gauge infusion set (Autosyringe Asiv 27/061, Travenol). The patients were encouraged to change the site of infusion every three days and experienced no difficulty with this. Two patients failed to respond to subcutaneous treatment and were therefore treated intravenously. Heparin 500 was added to the solution of luteinising hormone releasing hormone (150 IU/ml) in these two patients, and the solution was infused through a fine cannula (Portex 200/300/010) inserted into a forearm vein.
Initially 3) . In the patients with primary amenorrhoea the uterine cross sectional area before treatment was significantly smaller (7 5 (SEM 1-7) Cm2; n-6) than that in the patients with secondary amenorrhoea (21 (3) Cm2; n=22) (p <0 01). In those cycles in which ovulation occurred, once a dominant follicle had been selected the uterus grew at a similar rate in both groups. Anovulation was reflected by lack of uterine growth. Initial uterine size did not influence fertility; two patients 
COMPLICATIONS OF TREATMENT
No problems resulted from the long term use of subcutaneous infusion cannulas, but in one patient treated intravenously phlebitis occurred at the site of infusion. This resolved with oral antibiotic treatment, and no organism was cultured from the blood or the cannula. Pump failures occurred on two occasions in the follicular phase and once in the luteal phase but were remedied within 24 hours and did not seem to impair the effect of treatment.
Discussion
Our study confirms the efficacy of low dose pulsatile infusion of luteinising hormone releasing hormone in anovulatory infertility resistant to treatment with clomiphene. The introduction of this technique has depended on the creation of reliable automatic portable devices for infusion. Several are currently available, and we are preparing a report of our own assessment of them. In the present study we used specially designed pumps (fig 1) , which had the advantage of being small, robust, highly reliable, and acceptable to all our patients.
The success of this form of treatment relies on the physiological characteristics of luteinising hormone releasing hormone. The hormone increases the responsiveness of the pituitary gonadotrope to further stimulation with the hormone, and this self priming effect occurs only when stimulation is in the form of discrete pulses. When the pulse frequency rises above a critical value pituitary sensitivity falls, possibly as a result of a loss of luteinising hormone releasing hormone receptors25 or possibly because of a postreceptor effect. 26 Our results confirm that, in women with hypogonadotrophic hypogonadism, when a constant dose of luteinising hormone releasing hormone is given at a constant pulse interval the pattern of endocrine changes (fig 3) is the same as that seen in spontaneous ovulation cycles. This strongly suggests that the hormone has only a permissive role in the neuroendocrine control of ovulation and that the factors controlling positive and negative feedback operate at the pituitary level.
Patients with clomiphene resistant anovulatory infertility and normal prolactinaemia usually require combined treatment with human menopausal gonadotrophin and chorionic gonadotrophin, and this treatment even when closely supervised is associated with a 20% or more risk of multiple pregnancy.27 In the present study multiple ovulation developed in only one patient. This woman was one of those given human chorionic gonadotrophin within 24 hours of ultrasonic diagnosis of ovulation of a dominant follicle. These data suggest that the major factor determining the low incidence of multiple conception seen in this study, and in spontaneous pregnancies, is the control provided by intact pituitary feedback mechanisms. The low incidence of multiple conceptions reported here together with hormone concentrations during induced cycles that are within the normal range for spontaneous cycles (fig 3) strongly support our policy of discarding endocrine surveillance in favour of ultrasonic monitoring of ovarian follicular development. (It is technically simple to assess changes in uterine size and thereby provide clinicians with a biological assay of follicular secretion of oestrogen.)
As almost all multiple conceptions reported in association with treatment with luteinising hormone secreting hormone have occurred in cycles in which chorionic gonadotrophin was used to support the corpus luteum'3 28 we have now stopped its use.
As well as avoiding this problem, continuing the infusion of luteinising hormone releasing hormone also offers effective support of the corpus luteum and permits early diagnosis of pregnancy by measurement of serum chorionic gonadotrophin concentrations.
Previous studies have suggested that a wide range of doses of luteinising hormone releasing hormone may be used, with adjustments according to the theoretical severity of the hypogonadotrophic hypogonadism."3 Despite the wide range of responses of luteinising hormone and follicle stimulating hormone in the diagnostic luteinising hormone releasing hormone test (fig 2) , we did not find these adjustments to be necessary, and all the patients reported on here responded to a standard dose of 15 ,ug/pulse. The pulse frequency of 90 minutes was selected from a study of normal ovulatory cycles21 and was found to be effective in both follicular and luteal phases. We are currently investigating the effect of reducing the pulse frequency during the luteal phase because spontaneous pulsatility of luteinising hormone is decreased at this time.
The route of infusion has been the subject of some dispute. Reid et al suggested that subcutaneous administration produces disordered follicular maturation.12 In separate studies we found that poor follicular progression occurs only with suboptimal doses of luteinising hormone releasing hormone but can be reversed by an increase in the dose. Using the subcutaneous route we failed to induce ovulation in only two patients, although in these women intravenous treatment at the same dosage was effective. We therefore consider that subcutaneous infusion is simple and safe and should be used initially in all patients with hypogonadotrophic hypogonadism.
Our study confirms 
Introduction
The high mortality among patients in the months after myocardial infarction and the existence of treatments that may prove beneficial to some survivors but harmful to others make it necessary to identify the variables that characterise patients likely to benefit from specific forms of treatment. It has been suggested that exercise testing early after infarction may identify such variables; one study showed that ST depression in lead CM5 induced by exercise early after infarction predicted death in the following year.' Akhras et al suggested that this ST change might be an indication for early coronary surgery because it represents hazardous but reversible ischaemia.2 If such findings were confirmed exercise testing after infarction might prove valuable in identifying patients who would benefit from early revascularisation. To evaluate the exercise test in this context we reviewed a consecutive population of patients who were able to undertake a limited exercise protocol early after infarction.
